2005 Clinical Trials Conditions 
CannaMD
APRIL 23, 2020
In a 2005 paper , Dr. Bob Melamede noted that endocannabinoid dysregulation might be a causal factor in the disease’s development, detailing how the Parkinson’s disease-related glutamatergic problems of lab rodents could be “suppressed by exo- as well as endocannabinoids.” To learn more about GB Sciences, see: GBSciences.com.
Greencamp
FEBRUARY 2, 2019
Examples include pneumonia, cancers, tuberculosis, chronic diarrhea, and inflammation-based conditions such as meningitis and encephalitis. Depending on what type of cell it is, but also the type of condition a person is struggling with, these factors determine the way how will a specific cell react to cannabinoids.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Medical Hypotheses (18 aug 2005).
Cannabis Law Report
NOVEMBER 24, 2021
Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. We also used manifest textual analysis to search for word frequencies, and specific conditions referred to in the articles retrieved. Spasticity from neurological conditions. Background. Conclusions. Bonini et al.
SMPL
MAY 26, 2020
Alas, Mr. Gardner wrote in 2005, that would require access to expensive testing equipment. In the fall of 2010, a Project CBD website was set up where anyone could look through studies organized by disease or condition. fast-tracked clinical trials of GW Pharmaceuticals’ 98 percent CBD drug, Epidiolex.
CannaMD
OCTOBER 7, 2019
Besides going against all the classic “munchies/stoner” stereotypes, this finding is especially puzzling as cannabis is often used to increase weight gain in patients with medical conditions such as HIV/AIDS and cancer. So why are medical marijuana patients gaining weight when they need to, but losing weight when they don’t?
Cannabis Law Report
OCTOBER 29, 2019
Wakshlag is well-known in the veterinary medicine community as the first doctor to conduct an efficacy study in dogs in a clinical trial at Cornell using ElleVet CBD/CBDA on dogs with multi-joint discomfort. The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement.
Expert insights. Personalized for you.
116 
Let's personalize your content